Insider Trading March 31, 2026

Bloomingdale’s CEO Sells $54,132 in Macy’s Shares After Option Exercise

Olivier Bron disposed of a small holding following recent vesting; Macy’s posts stronger-than-expected Q4 2025 results amid mixed analyst reactions

By Priya Menon M
Bloomingdale’s CEO Sells $54,132 in Macy’s Shares After Option Exercise
M

Olivier Bron, chief executive of Bloomingdale’s, reported the sale of 3,051 Macy’s shares on March 30, 2026, netting $54,132 at a weighted average price of $17.7424. The transaction followed an option exercise and RSU vesting on March 28 that added 7,504 shares at no cost. Macy’s recent quarterly results beat expectations, but fiscal 2026 guidance and analyst price-target adjustments have introduced near-term uncertainty.

Key Points

  • Olivier Bron sold 3,051 Macy’s shares on March 30, 2026, at a weighted average price of $17.7424, totaling $54,132; trade prices ranged from $17.5500 to $17.8850.
  • Bron exercised options tied to restricted stock units on March 28, 2026, receiving 7,504 shares at a price of $0; after these moves he holds 15,672 Macy’s shares directly.
  • Macy’s outperformed Q4 2025 expectations with adjusted EPS of $1.67 and revenue of $7.6 billion, prompting mixed analyst responses and several price-target adjustments that reflect concerns over fiscal 2026 guidance and valuation.

Olivier Bron, who leads Bloomingdale’s - a division of Macy’s Inc - disclosed a sale of Macy’s common stock amounting to 3,051 shares on March 30, 2026, a transaction reported on a Form 4 filed with the Securities and Exchange Commission. The shares sold at a weighted average price of $17.7424, producing total proceeds of $54,132. Traded prices for the lot ranged between $17.5500 and $17.8850.

The transaction followed an exercise on March 28 in which Bron acquired 7,504 shares as a result of restricted stock units vesting. Those shares were obtained at a price of $0, reflecting their status as RSUs converted into common stock upon vesting.

After these movements, Bron's direct ownership in Macy’s stands at 15,672 shares. At the time of the sale, Macy’s common stock was trading at $18.10. The share price is 19% lower on a year-to-date basis, while it has appreciated 46% over the past 12 months.


Valuation snapshot

InvestingPro data cited in the filing note that Macy’s trades at a price-to-earnings ratio of 7.8 and yields a dividend of 4.36% at current levels. Those metrics are presented alongside the insider transaction but do not change the documented details of Bron’s holdings or the sale proceeds.


Recent financial performance and analyst responses

Macy’s reported fourth-quarter 2025 adjusted diluted earnings per share of $1.67, above a consensus forecast of $1.56. Revenue for the quarter came in at $7.6 billion versus an expected $7.46 billion.

Following the results, Jefferies maintained a Buy rating on Macy’s stock with a $22.00 price target. The firm’s stance was issued despite Macy’s fiscal 2026 guidance coming in below Wall Street estimates; the company attributed that guidance shortfall to accounting changes and store closures.

Other firms adjusted their targets in different directions. TD Cowen lowered its price target to $20 from $21, noting a 6% earnings beat and a 1.8% rise in comparable sales driven by strength in fragrance and luxury categories. Telsey reduced its target to $20 from $25 while highlighting better-than-expected sales, gross margin, and operating expense outcomes. Evercore ISI trimmed its target to $19 from $21, citing valuation concerns even as Macy’s same-store sales and EBIT margin exceeded expectations.


Context and implications

The transactions reported by Bron consist of a modest sale following the conversion of RSUs into shares. The sale amount and resulting ownership position are disclosed in regulatory filings, while recent operating results and analyst target changes provide the market backdrop against which the insider activity occurred.

As disclosed, the company’s most recent quarter outperformed expectations on both EPS and revenue, but guidance and accounting-related factors have led to mixed analyst reactions and target adjustments. The information here is limited to the transactions, current ownership, valuation metrics, quarterly results, and subsequent analyst actions as stated in the filing and related notes.

Risks

  • Fiscal 2026 guidance for Macy’s came in below Wall Street estimates, a development attributed to accounting changes and store closures - a factor that may affect retail sector sentiment.
  • Analyst price-target reductions and explicit valuation concerns from firms like Evercore ISI indicate uncertainty about Macy’s near-term valuation despite recent operational beats, potentially influencing investor perception in the consumer discretionary sector.
  • Insider selling, though limited in dollar value, occurs alongside mixed analyst commentary and guidance shortfalls, introducing a degree of informational uncertainty for market participants tracking retail and luxury goods demand.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026